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Abstract
Objectives: The aim was to determine the direct impact of the COVID-19 pandemic on Spain’s health budget.
Methods: Budget impact analyses based on retrospective data from patients with suspected severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) admitted to a Spanish hospital between February 26 and May 21,
2020. Direct medical costs from the perspective of the hospital were calculated. We analyzed diagnostic tests,
drugs, medical and nursing care, and isolation ward and ICU stays for three cohorts: patients seen in the
emergency room only, hospitalized patients who tested positive for SARS-CoV-2, and patients who tested negative.
Results: The impact on the hospital’s budget for the 3 months was calculated at €15,633,180, 97.4% of which was
related to health care and hospitalization. ICU stays accounted for 5.3% of the total costs. The mean cost per
patient was €10,744. The main costs were staffing costs (10,131 to 11,357 €/patient for physicians and 10,274 to
11,215 €/patient for nurses). Scenario analysis showed that the range of hospital expenditure was between
€14,693,256 and €16,524,924. The median impact of the pandemic on the Spanish health budget in the sensitivity
analysis using bootstrapped individual data was €9357 million (interquartile range [IQR], 9071 to 9689) for the
conservative scenario (113,588 hospital admissions and 11,664 ICU admissions) and €10,385 million (IQR, 110,030 to
10,758) for the worst-case scenario (including suspected cases).
Conclusion: The impact of COVID-19 on the Spanish public health budget (12.3% of total public health
expenditure) is greater than multiple sclerosis, cancer and diabetes cost.
Keywords: Costs and cost analysis, COVID-19, Health care costs, Clinical laboratory tests, Hospitalization, Budgets
Introduction
Coronavirus disease 2019 (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), was declared a pandemic by the World Health
Organization. By the end of June, it had affected 188
countries, with over 9 million confirmed cases and rising
infection rates [1]. A variety of public health measures
have been adopted to control the pandemic and ease the
burden on healthcare systems [2].
The long-term health consequences and potential se-
quelae of COVID-19 are unknown [3, 4], but the social
and economic impacts are already worse than those of
the Second World War [3]. While major COVID-19-
related research efforts are underway, there is a paucity
of studies examining the impacts of the pandemic on
public health budgets. This information is crucial to cor-
rectly manage the ongoing crisis, prepare for second
waves [5], and guide the implementation and manage-
ment of new services such as telemedicine or the
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creation of dedicated COVID-19 clinic units. Budget in-
formation is also needed to establish intervention-
specific costs and is essential for analyzing the cost-
effectiveness of new treatments for COVID-19. It can
also help identify diagnostic groups that should allow for
improved management.
The aim of this study was to conduct a hospital budget
impact analysis to assess the impact of COVID-19 at its
peak on the Spanish public health budget.
Methods
Study design, population, and resources
We estimated the impact of COVID-19, considering all
direct medical costs, on the Spanish public health budget
by extrapolating data from a retrospective cohort study
covering a period of 86 days during the peak of the pan-
demic. The study was conducted in a 252-bed Spanish
hospital that serves a catchment area of 187,258 people.
It was registered with the Spanish Agency of Medicines
and Medical Products (AEMPS) and approved by the
hospital’s ethics committee. Verbal informed consent in
the presence of a witness was obtained from all patients
and noted in the patients’ medical records. This proced-
ure was authorized by the Spanish Health authorities in
view of the exceptional epidemiological situation. Eli-
gible patients were adults (> 18 years) with suspected
COVID-19 who visited the hospital’s emergency room
(ER) between February 26 and May 21, 2020. Pregnant
women were excluded. In cases of readmission, data
from the first admission only were analyzed.
The patients were classified into three cohorts: 1)
those not requiring hospital admission (ER cohort), 2)
those admitted to the hospital and who received a posi-
tive real-time polymerase chain reaction (RT-PCR) result
within 24 h (SARS-CoV-2-positive cohort), and 3) those
admitted to the hospital and who received a negative
RT-PCR result within 24 h (SARS-CoV-2-negative
cohort).
Individual records of all patients in the ER cohort were
reviewed to identify the tests performed (RT-PCR, chest
X-ray, and blood tests [complete blood count, biochem-
ical parameters, coagulation test]. A record was also
made of time spent in the ER for all patients. Stays of
16 h or less were classified as medical visits, while longer
stays were classified as ER stays.
Individual information was also collected on all tests
performed during hospitalization. These included RT-
PCR, imaging studies, blood tests [complete blood count,
biochemical parameters, coagulation test], blood gas
analysis, other laboratory tests (ferritin, D-dimer, C-
reactive protein, and procalcitonin), and microbiological
tests (blood cultures and testing for multiple atypical re-
spiratory pathogens). We also calculated lengths of in-
tensive care unit stays (ICU stays) and isolation ward
stays (general stays). For the SARS-CoV-2-negative co-
hort, we calculated resources used in the first 48 h of
hospitalization, as this was the maximum time for re-
ceiving RT-PCR results. We also analyzed survival at the
end of follow-up for SARS-CoV-2-positive and -negative
cohorts.
Costs
Direct medical costs from the perspective of the hospital
were calculated in 2020 Euros (€). Discounts and indir-
ect or intangible costs were not considered. Unit costs
for ER and ICU stays, hospitalization, and staff salaries
were obtained from the official rates established for our
hospital for 2020 and checked against rates for several
hospitals in different regions of Spain [6]. These were
then multiplied by resource use data for each cohort to
provide a combined total. Drug prices were obtained
from the hospital’s pharmacy department. The main
drug groups considered were antivirals, anti-
inflammatories, antibiotics, antihypertensives, and gas-
troprotectives. We also computed the costs of laboratory
tests and imaging studies performed during
hospitalization. We do not include in our analyses indir-
ect cost because our cohort is mainly hospitalized
patients.
Once we had calculated the costs for the three cohorts,
we estimated the impact of the COVID-19 pandemic for
the period analyzed on the hospital’s budget for each co-
hort. The patients in the SARS-CoV-2-negative cohort
were included as they had come to the hospital because
they thought they had COVID-19 and would not have
come had the pandemic not existed. As these criteria
might vary according to the research team, we applied
two additional approaches to estimate the total impact.
1) In the first case, we calculated the impact of the
pandemic for ER and SARS-CoV-2-positive cohorts
only.
2) In the second case, we estimated a false-negative
rate of 29% [7], as the true rate was not available. In
other words, we assumed that 29% of SARS-CoV-2-
negative patients were actually infected and would
have returned to the hospital for care, thereby add-
ing to the costs.
Estimation of the National Level
Using official data reported for COVID-19-related hos-
pital and ICU stays in Spain in June 2020 [8], we esti-
mated the global impact of COVID-19 on the Spanish
health budget using a linear approach. The number of
cases for the ER cost analysis was estimated by calculat-
ing the ratio of SARS-CoV-2-positive patients to both
ER patients (1:3.58) and SARS-CoV-2-negative patients
(1:1.32) at our hospital.
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We evaluated two scenarios: a conservative scenario
for which we calculated the costs associated with the of-
ficial cases reported for Spanish hospitals (113,558 hos-
pital admissions and 11,664 ICU admissions) [8] and a
worst-case scenario for which we assumed that 52.2% of
SARS-CoV-2-positive patients would be hospitalized and
that 5.9% of these would require ICU admission [8]. In
these cases, the missing values were filled using linear
interpolation, giving 115,877 hospital admissions and
14,806 ICU admissions.
Sensitivity analyses
We performed univariate sensitivity analysis to assess
the uncertainty surrounding all the parameters in our
study. Considering the potential uncertainty arising from
differences in clinical practice across Spain, we estimated
and compared ranges of unit costs for seven autono-
mous communities: Andalusia, the Canary Islands, Can-
tabria, Catalonia, Madrid, Navarre, and the Basque
Country (supplementary material Table S1).
We finally performed a probabilistic sensitivity analysis
by bootstrapping individual patient data to obtain the
most realistic estimates possible [9]. The bootstrap ap-
proach is a non-parametric method that makes no distri-
butional assumptions concerning the statistic in
question. Instead, it employs the original data in a re-
sampling exercise in order to give an empirical estimate
of the sampling distribution of that estimate keeping the
correlations between the costs and effects of our
population.
We generated 1500 bootstrap samples for each cohort
using the size of the original sample and performing re-
sampling with replacement. For each subsample, we cal-
culated mean costs and budget impacts for the reference
hospital and Spain as a whole.
Main assumptions
1) Personal protective equipment (PPE) costs (which
have spiraled during the COVID-19 pandemic)
were calculated as hospitalization costs. Indirect
costs were not included for the lack of information.
2) Even though PPE and disinfectant costs have
increased substantially because of the pandemic,
price increases were not contemplated in our
analyses.
3) Staff overtime telework outside ordinary working
hours, and increased workload in other
departments (e.g., laundry services) were not
considered.
4) Future cost projections were not calculated, as the
COVID-19 sequelae are not yet well known. Indi-
vidual patient requirements during hospitalization
or after discharge were also not contemplated.
5) Even though antibiotics are not recommended as
prophylactic agents for COVID-19, they were in-
cluded in the cost analyses as they are part of the
workflow at our hospital.
6) The calculations for ICU costs included unit costs
and complete blood count, blood gas analysis, and
chest X-ray costs.
Microsoft Excel 2010 was used for analyzing the initial
scenario, modelling, bootstrapping, and the sensitivity
analysis, while SPSS for Windows 26 (IBM Corp. Re-
leased 2010) was used to compare cohorts.
Results
We evaluated 1602 patients, of whom 1446 fulfilled the
inclusion criteria. Their characteristics are summarized
in Table 1. Between February 26 and May 21, 2020, 912
patients tested positive for SARS-CoV-2 by RT-PCR.
Based on the total catchment population for our hospital
(187,258), this corresponds to a rate of 487 cases per
100,000 population.
The total estimated impact of COVID-19 on the hos-
pital’s budget for the 86 days analyzed was €15,633,180.
The vast bulk of this spending (94.7%) was related to the
treatment and management of SARS-CoV-2-positive pa-
tients admitted to hospital. The mean cost per patient
was €10,744 (€307 for the ER cohort, €1710 for the
SARS-CoV-2-negative cohort, €50,132 for the SARS-
CoV-2-positive cohort without ICU admission, and
€280,956 for the SARS-CoV-2 positive cohort with ICU
admission. The breakdown of costs per cohort is given
in Table 2.
The main cost components in the SARS-CoV-2-posi-
tive cohort were hospital care and hospitalization, at
€14,423,298 (97.4% of total); laboratory tests, at €177,359
(1.2%); imaging tests, at €126,204 (0.9%); and drugs, at
€84,078 (0.6%).
ICU stays accounted for 5.3% of the total cost
(€823,415.13). This cost corresponded to 9 patients
(3.54% of the SARS-CoV-2-positive cohort) with a mean
(SD) stay of 37.8 (12.9) days. ICU care accounted for
5.6% of the total cost for the overall SARS-CoV-2-posi-
tive cohort and 32.6% of the total cost for the SARS-
CoV-2-positive cohort with ICU admission. ICU staffing
costs were €103,661 (12.6%) for physicians and €255,556
(31.0%) for nursing staff. The cost of ICU stays for the
SARS-CoV-2-positive cohort was €464,199 (56.4%).
The most used antiviral treatment was hydroxychloro-
quine combined with azithromycin, but lopinavir/ritona-
vir (€4335, 43.2%) and gamma interferon (€3594, 35.8%)
were by far the largest cost components in this drug cat-
egory. The most expensive treatment was tocilizumab
(€27,213). Testing costs were mainly driven by RT-PCR
tests (€94,418) and procalcitonin (€33,388). Imaging
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studies, at €238,037, accounted for just 1.5% of the total
costs for all patients admitted (SARS-CoV-2-positive
and -negative).
According to the results of the parametric sensitivity
analysis, if the RT-PCR test-negative patients had not
been treated, the total impact on the hospital’s budget
would have been €14,693,256€ (€12,980 per patient).
Likewise, if we assume a non-false-negative rate, the
total cost would have been €19,376,071 (€17,117 per
patient).
Estimation of the National Level
In the conservative scenario, the total estimated impact
of the COVID-19 pandemic on the Spanish public health
budget was €9375 million; 1.5% of this cost corre-
sponded to the ER cohort, 3.0% to the SARS-CoV-2-
negative cohort, 63.2% to the SARS-CoV-2-positive co-
hort without ICU admission, and 32.3% to the SARS-
CoV-2-positive cohort with ICU admission (Table 3). In
the worst-case scenario, the total impact was €10,392
million (€139 million for the ER cohort, €284 million for
the SARS-CoV-2-negative cohort, €5809 million for the
SARS-CoV-2-positive cohort without ICU admission,
and €4160 million for the SARS-CoV-2-positive cohort
with ICU admission) (Table 3).
At the time of writing (end of June 2020), the pan-
demic is still going on and the total number of cases,
hospitalizations, and ICU admissions continues to rise.
Assuming that the total number of hospitalizations re-
mains below 185,000 and ICU admissions remain below
25,000, the estimated budget impact of the pandemic
should remain below €15,000 million (Table 4).
Sensitivity analysis
The main sources of cost variation were physician salar-
ies (range, €10,131 to €11,357/patient), nursing staff sal-
aries (€10,274 to €11,215/patient), and general stays
(€10,612 to €10,876/patient). The budget impact ranged
from €14,741,399 to €16,524,924 for hospitals and from
€15,050,529 (€10,344/patient) to €16,913,800 (€11,625/
patient) for regions.
The probabilistic analysis showed that the total median
impact of the COVID-19 pandemic on the hospital
budget was €15,581,235 (Fig. 1). By cohort, the median
impact was €14,754,694 for the SARS-CoV-2-positive
cohort, €551,592 for the SARS-CoV-2-negative cohort,
and €269,947 for the ER cohort.
Median per-patients costs in the SARS-CoV-2-positive
cohort were €53,373 for general stays, €3108 for ICU
stays, €692 for laboratory tests, €497 for diagnostic tests,
and €330 for drugs. In the SARS-CoV-2-negative cohort,
the median per-patient costs were €1098 for general
stays, €346 for diagnostic tests, €252 for blood tests, and
€13 for drugs. The median cost per patient in the ER co-
hort was €307.
The median estimated impact on the Spanish public
health budget was €9357 million (interquartile range
(IQR), €9071 to €9689 million) for the conservative sce-
nario and €10,385 million (IQR, €10,030 to €10,758 mil-
lion) for the worst-case scenario (Fig. 2).
Discussion
The COVID-19 impact on the Spanish public health
budget during the peak of the pandemic (86 days), con-
sidering direct medical costs only, was estimated at over
€9.4 billion (12.3% of total public health expenditure)
[10]. This is greater than the impact reported for numer-
ous conditions in Spain, such as multiple sclerosis (€1.4
billion) [11], cancer (€4.8 billion) [12], and diabetes (€5.8
billion) [13]. These figures give a picture of how big the
cost of the pandemic has been at its peak in Spain. The
overall impact on the healthcare system, however, can
be assumed to be even greater, as care provision for
other diseases was disrupted during the peak of the pan-
demic, as occurred in 68% of countries in Europe [14,
15]. In Spain, for example, the number of percutaneous
coronary interventions to treat myocardial infarction fell
Table 1 General characteristics of the study population
ER cohort SARS-CoV-2-positive cohort SARS-CoV-2-negative cohort
Total patients, n 989 265 348
< 18 years old, n 111 2 7
Readmissions, n – 9 18
Patients included, N 878 254 323
Age, mean (SD) 49.3 (16.2) 68.4 (15.9) 70.7 (17.9)
Male, n (%) 381 (43.4) 139 (54.7) 174 (53.9)
Deaths, n (%) 3 (0.3) 43 (16.9) 32 (9.9)
Days of hospitalization, mean (SD) 1 (0.1) * 44.1 (4.8) 8.3 (1.7)
Days in ICU, mean (SD) 0 (0.1) 37.8 (4.3) 4.7 (1.9)
ER, emergency room; ICU, intensive care unit; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation; ICU, intensive care unit
* Stays of 16 h or less were classified as medical visits, while longer stays were classified as ER stays
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Table 2 Impact on study hospital budget
Cost in € 2020
Items ER cohort* SARS-CoV-2-positive cohort SARS-CoV-2-negative cohort
Diagnostic tests
RT-PCR for SARS-CoV-2 47,855.80 25,673.99 20,888,41
Complete blood count – 3745.74 1949,48
Laboratory test† 19,075.58 10,745.74 5574.59
Coagulation† – 25,264.79 13,130.77
Microbiology‡ – 169.44 1279.36
Blood gas analysis – 12,287.42 6606.97
D dimer – 8620.25 4255.46
C-reactive protein – 7481.50 3861.00
Ferritin – 5758.36 3173.56
Procalcitonin – 21,370.62 12,017.19
Troponin – 12,613.64 6835.14
Interleukin 6 327.00 1918.40
ICU tests – 43,775.00 0.00
Total test costs 66,931.38 177,359.34 81,490.33
Drugs
Antivirals – 10,034.86 691.36
Corticosteroids – 1007.80 192.20
Tocilizumab – 27,212.75 0.00
Others, anti-inflammatory – 5115.51 53.44
Low-molecular-weight heparins – 6272.06 1123.29
Antibiotics§ – 2868.16 1795.92
Mucolytics – 383.74 81.40
ACE inhibitors/ARBs 64.10 18.99
Beta-blockers – 29.21 8.95
Calcium antagonists – 19.88 4.38
Alpha-blockers – 19.08 6.84
Diuretics – 7.92 1.74
Statins – 19.76 5.37
Proton pump inhibitors – 285.22 87.36
Analgesics – 219.10 44.15
Antithrombotics – 0 195.52
Drugs in ICU – 30,519.30 0.00
Total drug costs 0.00 84,078.45 4310.91
Imaging tests
Chest X-ray, portable 36,533.58 73,108.77 26,880.06
Computed tomography angiography 0.00 53,095.50 84,952.80
Total imaging costs 36,533.58 126,204.27 111,832.86
Hospitalization
Medical visits – 5,933,775.37 1951,26
Nursing hours – 6,095,260.01 2004,36
ER stays 166,492,90 – –
Hospitalization stays – 1,570,847.58 350,648.36
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by 40% during the pandemic [16], increasing future risks
and potential costs.
The mean cost estimated for treating a patient with
suspected or confirmed COVID-19 at our hospital was
€10,744. While this is lower than the costs of preterm
birth, specialized surgical procedures, or treatments for
solid cancer, it is higher than those of most procedures
in a medium-sized hospital such as ours, where treating
a patient with septicemia requiring mechanical ventila-
tion for more than 96 h, for example, costs €9087.
Our budget impact analysis of the COVID-19 pan-
demic in Spain will be a useful tool for hospital and de-
partment planning and preparedness purposes. Our
findings may also be of help to other countries wishing
to forecast the impact of the pandemic on their
healthcare systems, although this would require adapta-
tion to local procedures and costs. Cost-estimation stud-
ies are also needed to document the investment and use
of public funds during the pandemic. Our estimates
could also help healthcare authorities and governments
design mitigation plans to protect the healthcare system
and prevent staff burnout. Disease prevention is increas-
ingly crucial for ensuring the well-being of both society
and the economy.
Although our hospital was equipped with additional
ICU beds during the initial phase of the pandemic, these
were insufficient to meet all our mechanical ventilation
needs, meaning that some patients needed to be trans-
ferred to other hospitals. We therefore performed a sen-
sitivity analysis in which we varied the percentage of
Table 2 Impact on study hospital budget (Continued)
Cost in € 2020
Items ER cohort* SARS-CoV-2-positive cohort SARS-CoV-2-negative cohort
Medical visits, ICU – 103,660.58 0.00
Nursing hours, ICU – 255,555.95 0.00
ICU stays§§ – 464,198.60 0.00
Total hospitalization costs 166,492,90 14,423,298.09 354,648.36
TOTAL
TOTAL cost 269,957.86 14,810,940.15 552,282.36
Cost / patient 307.47 58,310.79 1709.85
ACE, angiotensin-converting enzyme; ARBs, angiotensin II receptor blockers; ICU, intensive care unit; RT-PCR, real-time polymerase chain reaction; SARS-CoV-2,
severe acute respiratory syndrome coronavirus 2
* Emergency room blood tests include complete blood count, biochemical profile, and coagulation test. Drugs are included as general care costs in the ER
** Includes glycemia, cholesterol, triglycerides, potassium, sodium, albumin, total protein, GPT, GOT, GGT, CPK, LDH, calcium, magnesium, phosphate, transferrin,
creatinine, urea, and bilirubin
† Includes: prothrombin time, APTT, and fibrinogen
‡ Includes blood culture, sputum culture, and tests for respiratory viruses (adenovirus, coronavirus, Middle Eastern Respiratory Syndrome, metapneumovirus,
rhinovirus, enterovirus, influenza A, influenza B, parainfluenza, respiratory syncytial virus, Bordetella pertussis, Chlamydophila pneumoniae, Mycoplasma pneumoniae)
§ Includes amoxicillin/clavulanic acid, vancomycin, ceftriaxone, linezolid, levofloxacin, moxifloxacin, ciprofloxacin, piperacillin/tazobactam, imipenem, meropenem,
ertapenem, daptomycin, and ceftoriden
§§ In the ICU, daily blood test and blood gas analysis
Table 3 Impact on Spanish public health budget
Cohort No. of patients Mean cost per patient Budget impact
(€ million)
Conservative scenario
ER cohort 432,854 €307.47 €133.09
SARS-CoV-2-negative cohort 159,239 €1709.85 €272.28
SARS-CoV-2-positive cohort without ICU stay 113,558 €50,131.99 €5692.89
SARS-CoV-2-positive cohort with ICU stay 11,664 €280,955.81 €3277.07
TOTAL €9375.32
Worst-case scenario
ER cohort 451,730 €307.47 €138.89
SARS-CoV-2-negative cohort 166,183 €1709.85 €284.15
SARS-CoV-2-positive cohort without ICU stay 115,877 €50,131.99 €5809.14
SARS-CoV-2-positive cohort with ICU stay 14,806 €280,955.81 €4159.82
TOTAL €10,391.99
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patients admitted to the ICU based on data from other
published cohorts (10.2%) [8]. The results showed an in-
crease in cost per patient from €10,744 to €13,411. ICU
stays accounted for 5.6% of total costs, even though just
3.5% of patients required ICU care. The main drivers of
costs were staff salaries and general and ICU stays
(97.8%). Drug treatments accounted for just 0.6% of total
costs and can therefore be considered a relatively small
cost component.
Using a prediction model for prolonged hospital stays
among patients with COVID-19 in China, Hong et al.
[17] estimated a mean cost per patient of €925 (IQR,
€636 to €1395), which is 11.6 times lower than the figure
calculated in our study. This difference could be due to
the relatively small sample size analyzed by Hong et al.
and the exclusion of patients with severe disease. In
addition, the study was not a formal cost-analysis study.
Another recent Chinese study of 70 patients hospitalized
for a median of 16 days (IQR, 10–20 days) estimated a
cost of $6827 per episode of COVID-19 [18], which is
closer to our figure. Nonetheless, the median length of
stay for SARS-CoV-2-positive patients in our series was
just 8 days (IQR, 5–15 days) but the cost per patient was
much higher, at €50,132. This difference can largely be
attributed to staff costs, as our study was performed dur-
ing the peak of the pandemic, when the hospital was
overstretched. Other possible reasons include cultural
differences and differences in healthcare system
organization and costs. A US study that developed a
Monte Carlo simulation model based on the assumption
that 80% of the population would become infected cal-
culated a total median direct medical cost of $654 billion
(95% CI: 615.8–692.8) [19], with a median cost of
$14,366 (95% CI: 13,545-15,129) per hospitalized patient
and $215 million (95% CI: 209–221) for symptomatic
patients. Our study, however, is based on real-world data
and is not comparable.
To date, two Spanish studies have been published.
Rodríguez-Gonzalez et al. [20] performed a cost analysis
in a referral hospital (n = 1255) with global costs (€ 0.44
million per 1000 hospitalized patient and € 408 per pa-
tient) similar to our results (€ 307 per patient). These
differences may be due to the higher incidence in
Madrid during the first wave of COVID-19. However,
we also present an estimate of the budgetary impact on
the national health system of € 9357 million, by carrying
out a probabilistic sensitivity analysis that took into ac-
count different incidence scenarios of the disease. In the
Fig. 1 Sensitivity analysis of the economic impact overall and by cohort (bootstrapping method). SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2
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second study [21] they make a totally theoretical esti-
mate based on gross domestic product and not on real
data like us.
Retrospective cohort studies are prone to selection
bias. In an attempt to minimize this risk, we included all
patients with suspected SARS-CoV-2 infection who vis-
ited the ER at our hospital. One notable strength of our
study is the use of individual-level data for both diagnos-
tic tests and treatments.
Another limitation of our study is related to possible
false-negative misclassifications. False-negative rates ran-
ging from 16 to 66% have been reported for RT-PCR, al-
though these have improved over time [7, 22]. The
prevalence of SARS-CoV-2 infection also varies by re-
gion, although the mean age and sex of hospitalized pa-
tients in our cohort were similar to those reported at the
national level (66 years and 55% males for general-stay
patients and 63 years and 55% males for ICU patients)
[8]. The main limitation of our study, however, is that
our calculations are based on data from a single hospital
and cannot therefore be generalized to hospitals with
other characteristics. Furthermore, to calculate the na-
tional costs, we assumed a constant ratio between nega-
tive and positive cohorts. Although, we analyzed the
uncertainty of this parameter in the sensitivity analysis,
readers must take attention that this relationship might
not be linear.
Finally, we did not analyze indirect costs, such as
productivity loss, but as most of the patients in the co-
hort were elderly and healthcare provider perspective.
Conclusions
The total estimated impact of COVID-19 on our hospi-
tal’s budget for a period of 86 days during the peak of
the pandemic was €15.6 million, or €10,744 per patient.
On extrapolating these estimates to Spain as a whole,
the total direct medical cost accrued up to the end of
June 2020 is €10.4 billion.
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